11:37:19 EDT Tue 15 Jun 2021
Enter Symbol
or Name

Login ID:
Medexus Pharmaceuticals Inc
Symbol MDP
Shares Issued 19,168,540
Close 2021-06-08 C$ 7.58
Recent Sedar Documents

Medexus offers triamcinolone hexacetonide in U.S.

2021-06-09 12:49 ET - News Release

Mr. Ken d'Entremont reports


Medexus Pharmaceuticals Inc. is initiating immediate availability of triamcinolone hexacetonide injectable suspension, USP (20 milligrams per millilitre) (TH) in the United States through the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) drug shortage program. More information about the FDA's Drug Shortage program is available at: FDA Drug Shortages.

TH is indicated for intra-articular, intrasynovial, or periarticular use in adults and adolescents for the symptomatic treatment of subacute and chronic inflammatory joint diseases, including: rheumatoid arthritis, juvenile idiopathic arthritis (JIA), osteoarthritis and post-traumatic arthritis, synovitis, tendinitis, bursitis and epicondylitis. To address the ongoing shortage of TH in the United States, Medexus is coordinating with Ethypharm, its licensing partner, to generate the data needed to support an Abbreviated New Drug Application (ANDA) filing in an expedited timeframe.

About Medexus

Medexus is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company's vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company's leading products are: Rasuvo{ਖ਼ ™} and Metojecttrademark, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITYtrademark, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B {஡ –} a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupalltrademark, an innovative prescription allergy medication with a unique mode of action.

We seek Safe Harbor.

© 2021 Canjex Publishing Ltd. All rights reserved.